Cargando…

CRISPR-Cas system: from diagnostic tool to potential antiviral treatment

ABSTRACT: This mini review focuses on the diagnosis and treatment of virus diseases using Crisper-Cas technology. The present paper describes various strategies involved in diagnosing diseases using Crispr-Cas-based assays. Additionally, CRISPR-Cas systems offer great potential as new therapeutic to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajan, Aishwarya, Shrivastava, Stuti, Janhawi, Kumar, Akhilesh, Singh, Alok Kumar, Arora, Pankaj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411046/
https://www.ncbi.nlm.nih.gov/pubmed/36008567
http://dx.doi.org/10.1007/s00253-022-12135-2
_version_ 1784775233060732928
author Rajan, Aishwarya
Shrivastava, Stuti
Janhawi
Kumar, Akhilesh
Singh, Alok Kumar
Arora, Pankaj Kumar
author_facet Rajan, Aishwarya
Shrivastava, Stuti
Janhawi
Kumar, Akhilesh
Singh, Alok Kumar
Arora, Pankaj Kumar
author_sort Rajan, Aishwarya
collection PubMed
description ABSTRACT: This mini review focuses on the diagnosis and treatment of virus diseases using Crisper-Cas technology. The present paper describes various strategies involved in diagnosing diseases using Crispr-Cas-based assays. Additionally, CRISPR-Cas systems offer great potential as new therapeutic tools for treating viral infections including HIV, Influenza, and SARS-CoV-2. There are several major challenges to be overcome before this technology can be applied routinely in clinical settings, such as finding a suitable delivery tool, toxicity, and immunogenicity, as well as off-target effects. This review also discusses ways to deal with the challenges associated with Crisper-Cas technology. KEY POINTS: • Crisper technology is being applied to diagnose infectious and non-infectious diseases. • A new generation of CRISPR-Cas-based assays has been developed which detect pathogens within minutes, providing rapid diagnosis of diseases. • Crispr-Cas tools can be used to combat viral infections, specifically HIV, influenza, and SARS-CoV-2.
format Online
Article
Text
id pubmed-9411046
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94110462022-08-26 CRISPR-Cas system: from diagnostic tool to potential antiviral treatment Rajan, Aishwarya Shrivastava, Stuti Janhawi Kumar, Akhilesh Singh, Alok Kumar Arora, Pankaj Kumar Appl Microbiol Biotechnol Mini-Review ABSTRACT: This mini review focuses on the diagnosis and treatment of virus diseases using Crisper-Cas technology. The present paper describes various strategies involved in diagnosing diseases using Crispr-Cas-based assays. Additionally, CRISPR-Cas systems offer great potential as new therapeutic tools for treating viral infections including HIV, Influenza, and SARS-CoV-2. There are several major challenges to be overcome before this technology can be applied routinely in clinical settings, such as finding a suitable delivery tool, toxicity, and immunogenicity, as well as off-target effects. This review also discusses ways to deal with the challenges associated with Crisper-Cas technology. KEY POINTS: • Crisper technology is being applied to diagnose infectious and non-infectious diseases. • A new generation of CRISPR-Cas-based assays has been developed which detect pathogens within minutes, providing rapid diagnosis of diseases. • Crispr-Cas tools can be used to combat viral infections, specifically HIV, influenza, and SARS-CoV-2. Springer Berlin Heidelberg 2022-08-26 2022 /pmc/articles/PMC9411046/ /pubmed/36008567 http://dx.doi.org/10.1007/s00253-022-12135-2 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Mini-Review
Rajan, Aishwarya
Shrivastava, Stuti
Janhawi
Kumar, Akhilesh
Singh, Alok Kumar
Arora, Pankaj Kumar
CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
title CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
title_full CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
title_fullStr CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
title_full_unstemmed CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
title_short CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
title_sort crispr-cas system: from diagnostic tool to potential antiviral treatment
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411046/
https://www.ncbi.nlm.nih.gov/pubmed/36008567
http://dx.doi.org/10.1007/s00253-022-12135-2
work_keys_str_mv AT rajanaishwarya crisprcassystemfromdiagnostictooltopotentialantiviraltreatment
AT shrivastavastuti crisprcassystemfromdiagnostictooltopotentialantiviraltreatment
AT janhawi crisprcassystemfromdiagnostictooltopotentialantiviraltreatment
AT kumarakhilesh crisprcassystemfromdiagnostictooltopotentialantiviraltreatment
AT singhalokkumar crisprcassystemfromdiagnostictooltopotentialantiviraltreatment
AT arorapankajkumar crisprcassystemfromdiagnostictooltopotentialantiviraltreatment